
AI Meets Biotech — and Hedge Funds Are Buying In
Caris Life Sciences’ IPO is backed by some of the industry’s biggest names as it pitches itself as a “next-gen TechBio” player.
Recent Articles
Caris Life Sciences’ IPO is backed by some of the industry’s biggest names as it pitches itself as a “next-gen TechBio” player.